No Data
No Data
Jiangsu Lianhuan Pharmaceutical (600513.SH): The controlling shareholder intends to increase its shareholding by no more than 0.5%.
On July 25th, Gelunhui announced that the controlling shareholder of Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., a trading company, increased its shares by 0.752 million shares, accounting for 0.26% of the total share capital of the company through the centralized bidding system of the Shanghai Stock Exchange. It also plans to continue to increase the proportion of the company's unrestricted tradable shares through the Shanghai Stock Exchange trading system (including but not limited to centralized bidding and bulk trading) within six months from the date of this increase, subject to the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange, and the cumulative increase shall not exceed the company's.
Lianhuan Pharmaceutical Scraps 450 Million Yuan Convertible Corporate Bond Issuance Plan
Jiangsu Lianhuan Pharmaceutical (600513.SH) terminated the issuance of convertible corporate bonds to unspecified parties.
Jiangsu Lianhuan Pharmaceutical (600513.SH) has announced the plan to issue convertible corporate bonds to unspecified parties...
Jiangsu Lianhuan Pharmaceutical (600513.SH): Plans to raise no more than 0.285 billion yuan through private placement.
On July 22, Gelunhui reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced the issuance of stocks to specific targets in 2024 through a simplified process. The total amount of funds raised through the issuance of stocks to specific targets through a simplified process shall not exceed CNY 0.285 billion (including this amount), shall not exceed CNY 0.3 billion and shall not exceed 20% of the net assets at the end of the latest year, and the net amount of funds raised after deducting the issuance expenses will be invested in the following projects: innovative drug LH-1801 development project and supplementary working capital.
Jiangsu Lianhuan Pharmaceutical Gets Drug Registration Certificate for Erectile Dysfunction Tablets
Jiangsu Lianhuan Pharmaceutical (600513.SH): Tadalafil tablets obtain pharmaceutical registration certificate.
Jiangsu Lianhuan Pharmaceutical (600513.SH) announced on July 8th that it has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for its pharmaceutical, Tadalafil Tablets. Tadalafil Tablets are a PDE5 inhibitor and phosphodiesterase inhibitor drug used to treat erectile dysfunction.
No Data